trial

Acute Glycine Pharmacodynamic Study

NCTId NCT01610011
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 21 (actual)
Sponsored by Mclean Hospital
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
21 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2010-07
Primary completion
2013-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Glycine administration

Sponsors

Mclean HospitalLead Sponsor
Brain & Behavior Research FoundationCollaborator

Investigators

1
Marc L. Steinberg, PH.D.Principal Investigator

Sites

1 total
Belmont, United States

Facts & assertions

4 sourced
Enrollment
21
Phase
NA
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
Glycine administration
drug
lead_sponsor
Mclean Hospital
company
collaborator
Brain & Behavior Research Foundation
company
indication
Psychotic Disorders
indication
Hyperglycinemia, Nonketotic
indication
Psychotic Disorders
indication
investigator
Marc L. Steinberg, PH.D.
person